APO RESEARCH · REPORT
Cabazitaxel
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Product & engineering
Understand the product.
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Selected research
Industry Research
Cabazitaxel Industry Research Report 2026
Market perspective
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
USA is the largest Cabazitaxel market with about 95% market share. Europe is follower, accounting for about 3% market share.The key manufacturers are Sanofi, Tapi Teva, Fuan Pharmaceutical Group, Fujian Yewpark Biological etc. Top 3 companies occupied about 99% market share.
Report Scope
Read the full market overview
This report quantifies the global Cabazitaxel market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cabazitaxel Market by Company
Sanofi
Tapi Teva
Fuan Pharmaceutical Group
Fujian Yewpark Biological
Cabazitaxel Segment by Type
Purity above 99%
Other Purity
Cabazitaxel Segment by Application
Age Below 65
Age Above 65
Cabazitaxel Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cabazitaxel market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cabazitaxel and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cabazitaxel.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cabazitaxel manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cabazitaxel by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cabazitaxel in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity above 99%
- Other Purity
Applications
- Age Below 65
- Age Above 65
Companies covered
- Sanofi
- Tapi Teva
- Fuan Pharmaceutical Group
- Fujian Yewpark Biological
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cabazitaxel Market Size (2021-2032)
- 2.2.2 Global Cabazitaxel Sales (2021-2032)
- 2.2.3 Global Cabazitaxel Market Average Price (2021-2032)
- 2.3 Cabazitaxel by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Purity above 99%
- 2.3.3 Other Purity
- 2.4 Cabazitaxel by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Age Below 65
- 2.4.3 Age Above 65
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cabazitaxel Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cabazitaxel Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Cabazitaxel Revenue of Manufacturers (2021-2026)
- 3.4 Global Cabazitaxel Average Price by Manufacturers (2021-2026)
- 3.5 Global Cabazitaxel Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cabazitaxel, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cabazitaxel, Product Type & Application
- 3.8 Global Manufacturers of Cabazitaxel, Established Date
- 3.9 Global Cabazitaxel Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Cabazitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Cabazitaxel Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Tapi Teva
- 4.2.1 Tapi Teva Company Information
- 4.2.2 Tapi Teva Business Overview
- 4.2.3 Tapi Teva Cabazitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Tapi Teva Cabazitaxel Product Portfolio
- 4.2.5 Tapi Teva Recent Developments
- 4.3 Fuan Pharmaceutical Group
- 4.3.1 Fuan Pharmaceutical Group Company Information
- 4.3.2 Fuan Pharmaceutical Group Business Overview
- 4.3.3 Fuan Pharmaceutical Group Cabazitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Fuan Pharmaceutical Group Cabazitaxel Product Portfolio
- 4.3.5 Fuan Pharmaceutical Group Recent Developments
- 4.4 Fujian Yewpark Biological
- 4.4.1 Fujian Yewpark Biological Company Information
- 4.4.2 Fujian Yewpark Biological Business Overview
- 4.4.3 Fujian Yewpark Biological Cabazitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Fujian Yewpark Biological Cabazitaxel Product Portfolio
- 4.4.5 Fujian Yewpark Biological Recent Developments
5 Global Cabazitaxel Market Scenario by Region
- 5.1 Global Cabazitaxel Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cabazitaxel Sales by Region: 2021-2032
- 5.2.1 Global Cabazitaxel Sales by Region: 2021-2026
- 5.2.2 Global Cabazitaxel Sales by Region: 2027-2032
- 5.3 Global Cabazitaxel Revenue by Region: 2021-2032
- 5.3.1 Global Cabazitaxel Revenue by Region: 2021-2026
- 5.3.2 Global Cabazitaxel Revenue by Region: 2027-2032
- 5.4 North America Cabazitaxel Market Facts & Figures by Country
- 5.4.1 North America Cabazitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cabazitaxel Sales by Country (2021-2032)
- 5.4.3 North America Cabazitaxel Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cabazitaxel Market Facts & Figures by Country
- 5.5.1 Europe Cabazitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cabazitaxel Sales by Country (2021-2032)
- 5.5.3 Europe Cabazitaxel Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cabazitaxel Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cabazitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cabazitaxel Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cabazitaxel Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cabazitaxel Market Facts & Figures by Country
- 5.7.1 South America Cabazitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cabazitaxel Sales by Country (2021-2032)
- 5.7.3 South America Cabazitaxel Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cabazitaxel Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cabazitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cabazitaxel Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cabazitaxel Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cabazitaxel Sales by Type (2021-2032)
- 6.1.1 Global Cabazitaxel Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Cabazitaxel Sales Market Share by Type (2021-2032)
- 6.2 Global Cabazitaxel Revenue by Type (2021-2032)
- 6.2.1 Global Cabazitaxel Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cabazitaxel Revenue Market Share by Type (2021-2032)
- 6.3 Global Cabazitaxel Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cabazitaxel Sales by Application (2021-2032)
- 7.1.1 Global Cabazitaxel Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Cabazitaxel Sales Market Share by Application (2021-2032)
- 7.2 Global Cabazitaxel Revenue by Application (2021-2032)
- 7.2.1 Global Cabazitaxel Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cabazitaxel Revenue Market Share by Application (2021-2032)
- 7.3 Global Cabazitaxel Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cabazitaxel Value Chain Analysis
- 8.1.1 Cabazitaxel Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cabazitaxel Production Mode & Process
- 8.2 Cabazitaxel Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cabazitaxel Distributors
- 8.2.3 Cabazitaxel Customers
9 Global Cabazitaxel Analyzing Market Dynamics
- 9.1 Cabazitaxel Industry Trends
- 9.2 Cabazitaxel Industry Drivers
- 9.3 Cabazitaxel Industry Opportunities and Challenges
- 9.4 Cabazitaxel Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst